Crossject

Equities

ALCJ

FR0011716265

Medical Equipment, Supplies & Distribution

Real-time Euronext Paris Other stock markets 05:19:40 2024-04-19 am EDT			5-day change	1st Jan Change
2 ^EUR	-1.96%		-0.74%	-59.76%

Apr. 03	CROSSJECT : Patience is a virtue… hopefully	AL
Apr. 02	Crossject Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Crossject : Publication of the 3rd Letter to the shareholders

July 31, 2015 at 09:31 am EDT

Publication of the 3^rd Letter to the shareholders

Chenôve, France, July 31^th 2015, 15h30 - CROSSJECT (ISIN: FR0011716265 ; Mnemo: ALCJ), the creator of ZENEO®, the world most advanced needle-free injection system, announces the publication of its 3^rd Letter to shareholders.

This new issue allows readers to discover the latest developments of our supergeneric products portfolio, with a focus on ZENEO® Sumatriptan and ZENEO® L15. The letter also deals with the strengthening of Crossject's IP through the filing of five new patents, and with the positive feedbacks that the company received in the United States.

The 3^rd Shareholders Letter is available on the website: www.crossject.com:
http://www.crossject.com/ (Media / Newsletter).

Next publication: 10 September, 2015 after market closure: Financial results for the 1^stsemester 2015

Contacts

Crossject

Patrick Alexandre / Timothée Muller

info@crossject.com

Citigate Dewe Rogerson

Laurence Bault /Lucie Larguier

+33 (0)1 53 32 84 78 / 84 75

laurence.bault@citigate.fr

lucie.larguier@citigate.fr

About CROSSJECT · www.crossject.com

Crossject is using its world-leading needle-free injection system, ZENEO(TM) to develop an attractive pipeline of high value SUPERGENERICS These needle-free products, which are based on well-known injectable drugs (chemicals & biologics), are designed to enhance patient safety, compliance and comfort.

Crossject's needle-free, pre-filled, single-use ZENEO(TM) injection systems are unique in that they can be tailored to deliver drugs intra-dermally, subcutaneously and intramuscularly. This means that ZENEO(TM) can allow a wide range of drugs and vaccines for a broad range on indications to be developed and approved in a very short period of time. Outside its own portfolio of SUPERGENERICS, Crossject anticipates partnering ZENEO with other pharma/biotech looking to improve the life cycle management of their key drugs or biologics.

CROSSJECT is listed on Alternext Paris (Mnemo: ALCJ, ISIN: FR0011716265).

Disclaimer

This document can contain information of an estimated nature. This information constitutes either trends or objectives and couldn't be regarded as previsions of a result or any other performance indicator. This information is submitted in a nature of risks and uncertainties, which are in certain cases out of control of the company, especially in the context of a R&D process. A more detailed description of these risks and uncertainties appears in the company's registration document, available on their website (www.crossject.com).

Publication of the 3rd Letter of shareholders:
http://hugin.info/160011/R/1942899/703114.pdf

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CROSSJECT via Globenewswire

HUG#1942899

Latest news about Crossject

CROSSJECT : Patience is a virtue… hopefully	Apr. 03	AL
Crossject Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 02	CI
CROSSJECT : Invest Securities slightly reduces its target	Feb. 28	CF
CROSSJECT : Securing the financing needs	Feb. 28	AL
Crossject: share price falls after convertible bond issue	Feb. 27	CF
Crossject Société Anonyme announced that it expects to receive ?12 million in funding	Feb. 25	CI
CROSSJECT : No news is not always good news...	Feb. 08	AL
Crossject: strategy advances, but visibility worries	Feb. 07	CF
CROSSJECT : Marketing initiative in the US	Jan. 06	AL
Crossject: Syneos Health hired for Zepizure in the USA	Jan. 05	CF
French Pharmaceutical Crossject Taps Syneos Health for US Commercialization of Epilepsy Rescue Treatment	Jan. 05	MT
CROSSJECT : A new distribution agreement in Northern Europe	Jan. 03	AL
France's Crossject Inks New Commercialization Deal for Epileptic Seizure Therapy in Northern EU	Dec. 22	MT
Crossject: commercial agreement in Northern Europe	Dec. 22	CF
Crossject Signs ZENEO(R) Commercialization Agreement for Northern Europe	Dec. 22	CI
CROSSJECT : H1 23: no surprises before the release of the detailed accounts in October	23-09-28	AL
Crossject Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-26	CI
Crossject Completes European, US Audits for Manufacturing of Seizure Medication for US	23-09-05	MT
AFT Pharmaceuticals Secures Australia, New Zealand License for Epilepsy Rescue Medication	23-07-20	MT
Crossject Société Anonyme Signs New Licensing Agreement on Zeno Midazolam Epilepsy Rescue Therapy with AFT Pharmaceuticals for Australia & New Zealand	23-07-20	CI
CROSSJECT : No real news in the FY22 results.	23-03-27	AL
CROSSJECT : FY22: not much to learn from the release	23-03-23	AL
Global markets live: Regeneron, Amazon, KKR, Moderna, UBS...	23-03-21
Crossject Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
CROSSJECT : Crossject has announced it has raised €14m in debt to finance its expansion.	23-01-12	AL

Chart Crossject

Duration

Period

More charts

Company Profile

Crossject specializes in manufacturing and marketing needleless drug self-injection. The group provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.

Sector

Medical Equipment, Supplies & Distribution

More about the company